MedTrace Logo

Montreal Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Device

NCT00571610 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2008-11-06

No results posted yet for this study

Summary

Reduction in mitral regurgitation due to safe placement of a PTMA device in the coronary sinus.

Conditions

Interventions

DEVICE

PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant

Percutaneous access from right or left subclavian vein, diagnostic assessment, then placement of the PTMA implant in the coronary sinus, great cardiac vein.

Sponsors & Collaborators

  • Viacor

    lead INDUSTRY

Principal Investigators

  • Luc Bilodeau, MD · Montreal Heart Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2008-04-30
Completion
2008-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00571610 on ClinicalTrials.gov